Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TRF Pharma
Burlingame, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TRF Pharma developed therapies for diseases involving aberrant cell adhesion to blood vessel walls, focusing on sickle cell disease and cancer metastasis. Its main clinical candidate was pentosan polysulfate sodium (TRF-1101), which reached Phase 2 trials in sickle cell disease but was ultimately discontinued. The company is now out of business.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecule (heparin derivatives and heparinoid drugs)Polysulfated polysaccharide (pentosan polysulfate sodium)
- Industry
- Biotech
Beyond the preview
Go deeper on TRF Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRF Pharma.